Next Article in Journal
Foamy Viruses, Bet, and APOBEC3 Restriction
Next Article in Special Issue
Amantadine Inhibits SARS-CoV-2 In Vitro
Previous Article in Journal
Establishment of a Reverse Genetic System from a Bovine Derived Influenza D Virus Isolate
Previous Article in Special Issue
The Combination of Bromelain and Acetylcysteine (BromAc) Synergistically Inactivates SARS-CoV-2

Treatment Protocol for COVID-19 Based on T2R Phenotype

Rhinology and Skull Base Research Group, Baton Rouge General Medical Center, 8585 Picardy Ave., Suite 210, Baton Rouge, LA 70809, USA
Department of Otorhinolaryngology, Cairo University, Cairo 11451, Egypt
Sinus and Nasal Specialists of Louisiana, Baton Rouge, LA 70809, USA
Author to whom correspondence should be addressed.
Academic Editors: Kenneth Lundstrom and Alaa A. A. Aljabali
Viruses 2021, 13(3), 503;
Received: 15 February 2021 / Revised: 12 March 2021 / Accepted: 16 March 2021 / Published: 18 March 2021
(This article belongs to the Special Issue Vaccines and Therapeutics against Coronaviruses)
COVID-19 has become a global pandemic of the highest priority. Multiple treatment protocols have been proposed worldwide with no definitive answer for acure. A prior retrospective study showed association between bitter taste receptor 38 (T2R38) phenotypes and the severity of COVID-19. Based on this, we proposed assessing the different T2R38 phenotypes response towards a targeted treatment protocol. Starting July 2020 till December 2020, we tested subjects for T2R38 phenotypic expression (supertasters, tasters, and nontasters). Subjects who were subsequently infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (diagnosed via PCR) were included. Based on their taster status, supertasters were given dexamethasone for 4 days; tasters were given azithromycin and dexamethasone +/− hydroxychloroquine for 7 days; and nontasters were given azithromycin and dexamethasone for 12 days. Subjects were followed prospectively and their outcomes were documented. Seven hundred forty-seven COVID-19 patients were included, with 184 (24.7%) supertasters, 371 (49.6%) tasters, and192 (25.7%) nontasters. The average duration of symptoms with the treatment protocol was 5 days for supertasters, 8.1 days for tasters, and 16.2 days for nontasters. Only three subjects (0.4%) required hospitalization (3/3 nontasters). Targeted treatment protocol showed significant correlation (p < 0.05) based on patients’ T2R38 phenotypic expression. Assessing treatment protocols for COVID-19 patients according to their T2R38 phenotype could provide insight into the inconsistent results obtained from the different studies worldwide. Further study is warranted on the categorization of patients based on their T2R38 phenotype. View Full-Text
Keywords: COVID-19; bitter taste receptors; T2R38; solitary chemosensory cells COVID-19; bitter taste receptors; T2R38; solitary chemosensory cells
Show Figures

Figure 1

MDPI and ACS Style

Taha, M.A.; Hall, C.A.; Shortess, C.J.; Rathbone, R.F.; Barham, H.P. Treatment Protocol for COVID-19 Based on T2R Phenotype. Viruses 2021, 13, 503.

AMA Style

Taha MA, Hall CA, Shortess CJ, Rathbone RF, Barham HP. Treatment Protocol for COVID-19 Based on T2R Phenotype. Viruses. 2021; 13(3):503.

Chicago/Turabian Style

Taha, Mohamed A., Christian A. Hall, Colin J. Shortess, Richard F. Rathbone, and Henry P. Barham. 2021. "Treatment Protocol for COVID-19 Based on T2R Phenotype" Viruses 13, no. 3: 503.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop